Medindia

X

Advanced Breast Cancer Drug Eribulin Rejected by NICE

by Kathy Jones on  November 18, 2011 at 8:30 PM Drug News   - G J E 4
British health regulator National Institute for Health and Clinical Excellence (NICE) has issued a final draft rejecting the prescription of breast cancer drug eribulin by the NHS for treating patients who have advanced breast cancer.
 Advanced Breast Cancer Drug Eribulin Rejected by NICE
Advanced Breast Cancer Drug Eribulin Rejected by NICE
Advertisement

The draft revealed that while the drug could extend patients' lives by 2.7 months on average, it came with a number of side effects, such as anemia, fatigue and hair loss, which other treatments did not have.

Advertisement
"Although the evidence presented to the independent advisory committee indicated that eribulin may help some patients live for a little longer, it also caused more undesirable side effects than other treatments already available, and the effects on health-related quality of life had not been adequately assessed", chief executive of NICE, Sir Andrew Dillon said.



Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All